A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BNC210 Compared to Placebo for the Acute Treatment of Social Anxiety Disorder
Latest Information Update: 18 Dec 2023
At a glance
- Drugs BNC 210 (Primary)
- Indications Social phobia
- Focus Therapeutic Use
- Acronyms PREVAIL
- Sponsors Bionomics
- 06 Dec 2023 According to a Bionomics Limited media release, data from this study were presented at the 2023 American College of Neuropsychopharmacology Annual Meeting.
- 06 Dec 2023 Results presented in a Bionomics Limited media release.
- 17 Oct 2023 According to a Bionomics media release, On October 11, Bionomics received the official meeting minutes from the EoP2 meeting with the FDA held on September 13, 2023 reflecting that Bionomics has reached an agreement with the FDA on.